GlassScriptPhysician profile
Farouk M Belal
NPI 1629053996
$2,582.37
in general payments reported to CMS, 2019-2025
26 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $218 · 2021: $236 · 2022: $138 · 2023: $559 · 2024: $590 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810 · Travel and Lodging: $117 · Education: $63.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.81 |
| Travel and Lodging | $116.50 |
| Education | $63.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $693.36 | 2024-2025 | Impella |
| Inari Medical, INC. | $275.65 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $238.64 | 2023-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.94 | 2020-2024 | Lifevest |
| Medtronic, INC. | $167.98 | 2024-2025 | Corevalve Evolut R, Reveal Linq, Mycarelink |
| Boston Scientific Corporation | $132.54 | 2020-2024 | Watchman Flx, Watchman Access System |
| Medtronic Vascular, INC. | $92.32 | 2020 | |
| Novartis Pharmaceuticals Corporation | $88.96 | 2023-2025 | |
| Scpharmaceuticals INC. | $87.09 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $73.46 | 2021 | |
| Lantheus Medical Imaging, INC. | $66.85 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.79 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $57.79 | 2024 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $56.75 | 2021-2024 | Uptravi, Opsumit |
| Biotronik INC. | $45.27 | 2021-2023 | Edora 8 Dr-T, Biomonitor |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $30.38 | 2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $30.35 | 2025 | Camzyos, Eliquis |
| Philips North America LLC | $28.81 | 2024-2025 | Event, (Ck4) Mcot |
| Cardiovascular Systems INC. | $25.97 | 2021 | |
| Cordis US Corp. | $20.62 | 2024 | Mynxgrip |
| Novo Nordisk INC | $17.10 | 2025 | Rybelsus, Ozempic |
| Preventice Services, LLC | $16.78 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.76 | 2023 | Jardiance |
| Vivaquant INC, Dba Rhythm Express | $12.00 | 2025 | Rhythm Express |
| Terumo Medical Corporation | $11.91 | 2021 | |
| Amgen INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farouk Belal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.